Members of our community often receive recognition for their outstanding contributions to their respective fields. This page showcases their accomplishments. Here you’ll find a list of current award opportunities, Department-sponsored funding, and a roundup of recent accomplishments.

New Funding Opportunities Related to COVID-19

These funding opportunities serve to address the urgent need to develop our understanding of the disease and to explore areas that inform treatment and outcomes. View a full list here. 

Patient-Centered Outcomes Research Institute (PCORI): PCORI Funding Opportunities for COVID-19-Related Enhancements to Existing PCORI-Funded Projects

Timeline: These funding opportunities are currently open and will be accepting applications on a rolling basis.

Program Announcement – for current Research Awardees

Program Announcement – for current Engagement Awardees

Program Announcement – for current Dissemination and Implementation Awardees

Purpose: Rooted in our mission to help people make informed healthcare decisions and improve healthcare delivery and outcomes, PCORI is poised to support work to provide answers to the challenging COVID-19 related dilemmas facing patients, caregivers, providers, health systems, and policymakers through targeted investments in extending our Research, Engagement Awards, and Dissemination and Implementation activities.  PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Budget: $150,000 – 500,000 limit (direct and indirect costs). Higher amounts may be considered on a case-by-case basis, based on applicant's justification of the proposed amount.

Department of Defense: Congressionally Directed Medical Research Programs FY20 Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award (for Emerging Viral Diseases and Respiratory Health)

Timeline: Pre-application/Letter of intent (required) deadline: June 8, 2020 via eBrap

Please include your RPM’s name as business official in the pre-application.

Institutional representative (RPM/RMG or CGO/OSR) deadline: June 15, 2020

Full proposal deadline: June 22, 2020 via grants.gov

Purpose: The PRMRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact in one or more of the Focus Areas published in this funding opportunity for the FY20 PRMRP Congressionally specified Topic Areas of Emerging Viral Diseases and Respiratory Health. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proofof-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

Budget: Applications are not restricted to a predetermined cost limit. The requested budget must be justified and appropriate to the scope of the clinical trial proposed.

Program Announcement

Department of Defense: Congressionally Directed Medical Research Programs FY20 Peer Reviewed Medical Research Program (PRMRP) Investigator-Initiated Research Award (for Emerging Viral Diseases and Respiratory Health)

Timeline: Pre-application/Letter of intent (required) deadline: May 28, 2020 via eBrap

Please include your RPM’s name as business official in the pre-application.

Institutional representative (RPM/RMG or CGO/OSR) deadline: June 5, 2020

Full proposal deadline: June 12, 2020 via grants.gov

Purpose: The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care in one or more Focus Areas published in this Funding Opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.

Budget: $1,600,000 Direct Costs (Partnering PI option: 2,000,000 Direct Costs)

Program Announcement

Department of Defense: Congressionally Directed Medical Research Programs FY20 Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award (for Emerging Viral Diseases and Respiratory Health)

Timeline: Pre-application/Letter of intent (required) deadline: May 28, 2020 via eBrap

Please include your RPM’s name as business official in the pre-application.

Institutional representative (RPM/RMG or CGO/OSR) deadline: June 5, 2020

Full proposal deadline: June 12, 2020 via grants.gov

Purpose: The PRMRP Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the FY20 PRMRP Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.

Budget: $4,000,000 Direct Costs

Program Announcement

National Cancer Institute: Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19)

Timeline: Applications will be accepted on a rolling basis from April 14, 2020, through June 25, 2020.

Purpose: The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs at the National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19). To accelerate the development of promising technologies, the NCI encourages applications from small businesses with NCI-funded active SBIR/STTR awards for technologies that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19).

Submission Information: For funding consideration, all applicants must designate "NOT-CA-20-043" in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.

National Cancer Institute: Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19)

Timeline: Applications will be accepted on a rolling basis from April 14, 2020, through June 25, 2020.

Purpose: The National Cancer Institute (NCI) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa. Topics of specific interest to NCI include understanding the basic mechanisms of interaction between SARS-CoV-2 and cancer cells, co-morbidities of cancer and SARS-CoV-2 infection (especially in disparately affected patient populations), and the impacts on treatment and clinical outcomes of SARS-CoV-2 infected persons in the context of cancer.

Submission Information: For funding consideration, all applicants must designate "NOT-CA-20-042" (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.

NCCIH: Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19)

Timeline: Applications will be accepted on a rolling basis through October 6, 2020.
Purpose: NCCIH is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches, that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

Submission Information: For funding consideration, all applicants must designate “NOT-AT-20-011” (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. Applications without this information in Box 4b will not be considered for this initiative.

Other Funding Opportunities 

Meet the 2019 Hewlett Award Recipient

The 2019 Hewlett Award winner was Mark S. Blumenkranz, MD, MMS, H. J. Smead professor of ophthalmology, emeritus. An extraordinarily gifted eye surgeon with a focus on vitreoretinal diseases, he has also succeeded in such administrative roles as head of the vitreoretinal service; department chairman for 18 years; and involvement in the planning, fundraising, and construction of the Byers Eye Institute of Stanford, which he served as founding director between 2010 and 2015.